Orlistat Overcoming Third-generation EGFR-TKI Resistance

Clinical trial NCT06818955 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06818955
Sponsor: Ping Peng
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Adenocarcinoma Osimertinib

Start date: 2025-02-16
Primary completion: 2025-05-15
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.